SOLBEC CONFIRMS TUMOR TARGETS FOR MULTIPLE-TARGET PHASE II TRIALS

Solbec has reported that malignant melanoma and metastatic renal cell carcinoma (mRCC) will be the first two tumor targets for its multiple-target activity trials of Coramsine for the treatment of advanced solid tumours

Coramsine has shown activity against a range of tumors in ex vivo, in vitro and in vivo studies. Phase I trial results highlighted mRCC and non-small cell lung cancer as potential targets. The ex vivo studies highlighted melanoma, endometrial cancer, breast cancer, colorectal cancer and mRCC as potential targets. Additional ex vivo studies commissioned showed that Coramsine, in conjunction with several widely used chemotherapeutic agents, displayed a synergistic action against both melanoma and mRCC.